Document Detail


Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
MedLine Citation:
PMID:  23172758     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: PAS is more effective than OCT in reducing hepatorenal cystogenesis in rodent models; therefore, it might be more beneficial for the treatment of PKD and PLD.
Authors:
Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Sergio A Gradilone; Bing Huang; Anatoliy I Masyuk; Marie C Hogan; Vicente E Torres; Nicholas F Larusso
Related Documents :
10330948 - Generic immunosuppressant use in solid organ transplantation.
17616278 - Novel immunosuppression: small molecules and biologics.
12615698 - Origin of vascular smooth muscle cells and the role of circulating stem cells in transp...
19136898 - Kidney transplant half-life (t[1/2]) after rapid discontinuation of prednisone.
15740568 - Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, la...
21440758 - Pulmonary complications in renal recipients after transplantation.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural     Date:  2013-03-06
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  58     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-26     Completed Date:  2013-08-30     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  409-21     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Cycle / drug effects
Cyclic AMP / metabolism
Cysts / drug therapy*
Humans
Liver Diseases / drug therapy*
Mice
Octreotide / metabolism,  therapeutic use*
Polycystic Kidney Diseases / drug therapy*
Polycystic Kidney, Autosomal Dominant / drug therapy
Rats
Receptors, Somatostatin / biosynthesis,  drug effects*,  metabolism
Somatostatin / analogs & derivatives*,  metabolism,  therapeutic use
Grant Support
ID/Acronym/Agency:
CA112281/CA/NCI NIH HHS; DK24031/DK/NIDDK NIH HHS; DK44863/DK/NIDDK NIH HHS; EB000305/EB/NIBIB NIH HHS; P30 DK084567/DK/NIDDK NIH HHS; P30 DK090728/DK/NIDDK NIH HHS; P30DK084567/DK/NIDDK NIH HHS; P30DK090728/DK/NIDDK NIH HHS; R01 DK024031/DK/NIDDK NIH HHS; R01 DK044863/DK/NIDDK NIH HHS; R01 EB000305/EB/NIBIB NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Somatostatin; 0/pasireotide; 0/somatostatin receptor 2; 0/somatostatin receptor 3; 0/somatostatin receptor type 1; 51110-01-1/Somatostatin; E0399OZS9N/Cyclic AMP; RWM8CCW8GP/Octreotide
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early development of the thymus in Xenopus laevis.
Next Document:  Transradial percutaneous coronary intervention for chronic total occlusion using sheathless techniqu...